Please login to the form below

Not currently logged in
Email:
Password:

AFFiRiS

This page shows the latest AFFiRiS news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer’s failure as Targacept trial disappoints

Another Alzheimer’s failure as Targacept trial disappoints

This June the UK's Medical Research Council (MRC) launched a £16m dementia research programme and Austrian biopharma company AFFiRiS claimed its drug candidate AD04 was the first therapy to show

Latest news

  • Burden of proof Burden of proof

    So AFFiRiS' recently announced 'breakthrough' should be a cause for celebration. ... And although AFFiRiS says AD04's results are the first ever to meet EMA and FDA criteria for disease modifications in Alzheimer's, the trial was not a controlled study

  • AFFiRiS claims a first in Alzheimer's disease therapy AFFiRiS claims a first in Alzheimer's disease therapy

    AFFiRiS claims a first in Alzheimer's disease therapy. Says AD04 is first drug to demonstrate disease modification. ... AFFiRiS, however, believes its data reveals a more profound impact using its vaccination approach.

  • Ali Alloueche to lead business strategy at Austrian biopharma Affiris

    In his new role Alloueche will oversee Affiris' business activities, strategic alliances and partnerships. ... Alloueche said: "Affiris is one of the most dynamic biopharmaceutical companies in Europe.

  • AFFiRiS Alzheimer vaccine begins efficacy trial

    AFFiRiS Alzheimer vaccine begins efficacy trial. AFFiRiS' Alzheimer's vaccine candidate AD02 has begun phase II clinical testing, with hopeful efficacy confirmation by 2012. ... Vienna-based AFFiRiS' Alzheimer's vaccine candidate AD02 has begun phase II

  • GSK Biologicals signs Alzheimer's deal with AFFiRiS

    The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. ... The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics